Physician profile
Daniel Trejo
NPI 1093766925
$2,554.81
in general payments reported to CMS, 2019-2025
24 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.29 · 2021: $277 · 2022: $479 · 2023: $428 · 2024: $681 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.79 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $440.54 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $419.23 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $345.29 | 2022-2025 | Vraylar |
| Astellas Pharma US INC | $327.02 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $166.59 | 2022-2024 | |
| Insulet Corporation | $136.38 | 2024-2025 | Omnipod, Omnipod |
| Esperion Therapeutics, INC. | $101.93 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $85.87 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.06 | 2021-2025 | Jardiance, Tradjenta |
| Medtronic, INC. | $68.98 | 2023-2025 | Minimed 780g, Minimed 770g |
| Lilly USA, LLC | $59.99 | 2021-2025 | Mounjaro |
| Amgen INC. | $57.27 | 2024 | Otezla, Repatha |
| Agios Pharmaceuticals, INC. | $51.81 | 2022-2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $37.07 | 2023 | Trelegy Ellipta |
| Ardelyx, INC. | $33.25 | 2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.58 | 2022 | |
| Sage Therapeutics, LLC | $20.00 | 2025 | Zurzuvae |
| Novartis Pharmaceuticals Corporation | $17.29 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.24 | 2021 | |
| Pfizer INC. | $15.74 | 2023 | |
| Exact Sciences Corporation | $15.28 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.78 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $13.86 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $13.76 | 2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Trejo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.